Acumen Pharmaceuticals Stock Forecast

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Acumen Pharmaceuticals stock have an average target of 6.67, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 182.63% from the current stock price of 2.36.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$6.67	$8.00	$8.00
Change	+69.49%	+182.63%	+238.98%	+238.98%

Analyst Ratings

The average analyst rating for Acumen Pharmaceuticals stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	6	6	6
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Zemansky Bank of America Securities	Bank of America Securities	Buy Maintains $8	Buy	Maintains	$8	+238.98%	Jun 11, 2026
Thomas Shrader BTIG	BTIG	Buy Maintains $8	Buy	Maintains	$8	+238.98%	Apr 2, 2026
Geoff Meacham Citi	Citi	Buy Maintains $4	Buy	Maintains	$4	+69.49%	Jan 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.58

from -2.00

EPS Next Year

-1.51

from -1.58

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-5.02	-1.06	-1.08	-1.71	-2.00	-1.35	-1.48
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	5	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-1.32	-1.35
Avg	-1.58	-1.51
Low	-1.76	-1.68

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.